+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years +
All Genders
ID05928039

Evaluating First-Line Biologic Treatments for Moderate-to-Severe Ileal Crohns Disease Using a Randomized, Parallel-Group Design

Led by University of Calgary · Updated on 2026-10-26

210

Participants Needed

23

Research Sites

74 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating three classes of biologic treatments for patients with moderate-to-severe Crohns disease that primarily affects the small bowel ileal-dominant. The study aims to find which biologic class leads to the highest number of patients achieving endoscopic remissionmeaning healed ulcers in the small bowelwithout needing corticosteroids after one year. All treatments used are approved by Health Canada and are studied in a real-world setting. Participants will be randomly assigned to one of three treatment groups at the start of the study a TNF antagonist infliximab or adalimumab, an anti-integrin agent vedolizumab, or an anti-IL23 targeted agent ustekinumab or risankizumab. These treatments are given according to standard care schedules using intravenous or subcutaneous administration at specific weeks and intervals during the study. Participants who are on corticosteroids will begin tapering off these within six weeks of starting their biologic therapy. During the study, participants will undergo evaluations at months 4, 8, and 12, including assessments using the Harvey Bradshaw Index HBI and EuroQOL 5-domain questionnaire EQ-5D, and tests for C-reactive protein and fecal calprotectin levels. At 12 months, a video-recorded ileocolonoscopy will determine if endoscopic remission has been achieved. The study will also monitor clinical remission, treatment persistence, safety, and quality of life over the one-year period.

CONDITIONS

Brief Title

PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease

Research Team

H

Harsha Ashton

C

Christopher Ma, MD MPH

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here